SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formulation

Version 11.0  Revision Date: 04/04/2023  SDS Number: 67748-00026  Date of last issue: 08/23/2022
Date of first issue: 02/27/2015

SECTION 1. IDENTIFICATION

Product name: Imipenem / Cilastatin / Relebactam Formulation

Manufacturer or supplier’s details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Combustible dust
Eye irritation: Category 2A
Respiratory sensitization: Category 1
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure: Category 2 (Kidney)

GHS label elements
Hazard pictograms:

Signal Word: Danger

Hazard Statements:
If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H319 Causes serious eye irritation.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Kidney) through prolonged or repeated exposure.
Precautionary Statements:

**Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
P285 In case of inadequate ventilation wear respiratory protection.

**Response:**
P304 + P341 IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.
P342 + P311 If experiencing respiratory symptoms: Call a doctor.

**Storage:**
P405 Store locked up.

**Disposal:**
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards:
Contact with dust can cause mechanical irritation or drying of the skin.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture:** Mixture

**Components**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>39.5</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>39.4</td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
<td>19.5</td>
</tr>
</tbody>
</table>

### SECTION 4. FIRST AID MEASURES

**General advice:** In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**If inhaled:** If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formulation

Version 11.0  Revision Date: 04/04/2023  SDS Number: 67748-00026  Date of last issue: 08/23/2022

Date of first issue: 02/27/2015

Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of the skin. Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

**Conditions for safe storage**
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

**Materials to avoid**
- Do not store with the following product types:
  - Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Inert or nuisance dust</th>
<th>TWA (total dust)</th>
<th>OSHA Z-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 Million particles per cubic foot</td>
<td>15 mg/m³</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dust, nuisance dust and particulates</th>
<th>TWA (respirable fraction)</th>
<th>OSHA Z-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 Million particles per cubic foot</td>
<td>5 mg/m³</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>TWA</td>
<td>5 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>TWA</td>
<td>1000 ug/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
<td>TWA</td>
<td>0.3 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Further information:** RSEN

**Engineering measures**
- Use feasible engineering controls to minimize exposure to compound.
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to
protect products, workers, and the environment.

**Personal protective equipment**

**Respiratory protection**
General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**
- **Material**: Chemical-resistant gloves

**Eye protection**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**
- **Material**: Work uniform or laboratory coat.

**Hygiene measures**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**: powder

**Color**: White to light yellow

**Odor**: No data available

**Odor Threshold**: No data available

**pH**: No data available

**Melting point/freezing point**: No data available

**Initial boiling point and boiling range**: No data available

**Flash point**: Not applicable
Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
   Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
   Viscosity, dynamic : No data available

   Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
   Can react with strong oxidizing agents.
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formulation

Version 11.0  Revision Date: 04/04/2023  SDS Number: 67748-00026  Date of last issue: 08/23/2022
Date of first issue: 02/27/2015

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cilastatin:
Acute oral toxicity: LD50 (Rat): 8,000 mg/kg
LD50 (Mouse): 8,000 mg/kg

Imipenem:
Acute oral toxicity: LD50 (Mouse): 10,000 mg/kg
Acute toxicity (other routes of administration): LD50 (Rat): > 2,000 mg/kg
Application Route: Intravenous
LD50 (Mouse): 1,500 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:

Cilastatin:
Species: Rabbit
Result: No skin irritation

Relebactam:
Method: EpiDerm
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.
Components:

Cilastatin:
- Species: Rabbit
- Result: Moderate eye irritation

Relebactam:
- Result: No eye irritation
- Method: Bovine cornea (BCOP)

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cilastatin:
- Routes of exposure: Skin contact
- Remarks: No data available
- Routes of exposure: Inhalation
- Remarks: No data available

Imipenem:
- Remarks: May cause sensitization of susceptible persons by inhalation of aerosol or dust.
- Routes of exposure: Skin contact
- Remarks: Not classified due to lack of data.

Relebactam:
- Test Type: Local lymph node assay (LLNA)
- Routes of exposure: Dermal
- Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Cilastatin:
- Genotoxicity in vitro: Test Type: Microbial mutagenesis assay (Ames test)
  Result: negative

Imipenem:
- Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-
tion

Test system: Chinese hamster lung cells
Result: negative

Test Type: reverse mutation assay
Result: negative

Test Type: unscheduled DNA synthesis assay
Result: negative

Test Type: Chromosomal aberration
Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo:
Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intravenous
Result: negative

Relebactam:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.
Components:

Cilastatin:
- Effects on fertility
  - Test Type: Fertility/early embryonic development
  - Application Route: Intravenous
  - Fertility: LOAEL: 1,000
  - Symptoms: No adverse effects.
  - Result: No effects on fertility and early embryonic development were detected.

Imipenem:
- Effects on fertility
  - Test Type: Fertility/early embryonic development
  - Species: Rat, male and female
  - Application Route: Intravenous
  - Fertility: LOAEL: 80 mg/kg body weight
  - Symptoms: No adverse effects., Reduced fetal weight.
  - Result: No effects on fertility and early embryonic development were detected.

  - Test Type: Fertility/early embryonic development
  - Species: Rat, male and female
  - Application Route: Subcutaneous
  - Fertility: LOAEL: 320 mg/kg body weight
  - Symptoms: No adverse effects., Reduced fetal weight.
  - Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development
- Test Type: Development
  - Species: Monkey
  - Application Route: Intravenous
  - Developmental Toxicity: LOAEL: 100 mg/kg body weight
  - Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

  - Test Type: Development
  - Species: Rabbit
  - Application Route: Intravenous
  - Developmental Toxicity: NOAEL: 60 mg/kg body weight
  - Result: No teratogenic effects.

  - Test Type: Development
  - Species: Rat
  - Application Route: Intravenous
  - Developmental Toxicity: NOAEL: 60 mg/kg body weight
  - Result: No teratogenic effects.

Reproductive toxicity - Assessment
- Some evidence of adverse effects on development, based on animal experiments.

Relebactam:
- Effects on fertility
  - Test Type: Pre-/postnatal development
  - Species: Rat
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-
tion

Application Route: Subcutaneous
Fertility: NOAEL: 450 mg/kg body weight

Effects on fetal development:

Test Type: Embryo-fetal development
Species: Rat
Application Route: Intraperitoneal injection
Embryo-fetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on fetal development.

Test Type: Embryo-fetal development
Species: Mouse
Application Route: Intraperitoneal injection
Embryo-fetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on fetal development.

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: >= 450 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on fetal development.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Kidney) through prolonged or repeated exposure.

Components:

Relebactam:

Target Organs: Kidney
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cilastatin:

Species: Rat
NOAEL: >= 500 mg/kg
Application Route: Intravenous
Exposure time: 90 Days
Remarks: No significant adverse effects were reported

Species: Monkey
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formulation

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>&gt;= 500 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>5 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

### Imipenem:

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>60 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>120 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>180 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

### Relebactam:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, female</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, male</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>450 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>25 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>37.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Species</td>
<td>Monkey</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

**Imipenem:**

- **Inhalation**
  - Symptoms: Nausea, Vomiting, Diarrhea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
  - Remarks: May cause sensitization of susceptible persons by inhalation of aerosol or dust.

**Relebactam:**

- **Skin contact**
  - Symptoms: Pain, Discomfort, Diarrhea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Cilastatin:**

- **Toxicity to fish**
  - LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203

- **Toxicity to daphnia and other aquatic invertebrates**
  - EC50 (Daphnia magna (Water flea)): > 99 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202

- **Toxicity to algae/aquatic plants**
  - EC50 (Anabaena flos-aquae): > 99 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 99 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

  - NOEC (Anabaena flos-aquae): 99 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

  - NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l
<table>
<thead>
<tr>
<th>Toxicity to fish (Chronic toxicity)</th>
<th>EC10 (Pimephales promelas (fathead minnow)): &gt; 9.9 mg/l Exposure time: 32 d Method: OECD Test Guideline 210</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</td>
<td>EC10 (Daphnia magna (Water flea)): &gt; 10 mg/l Exposure time: 21 d Method: OECD Test Guideline 211</td>
</tr>
<tr>
<td>Toxicity to microorganisms</td>
<td>EC50: &gt; 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209</td>
</tr>
</tbody>
</table>

**Imipenem:**

<table>
<thead>
<tr>
<th>Toxicity to daphnia and other aquatic invertebrates</th>
<th>EC50 (Daphnia magna (Water flea)): &gt; 78 mg/l Exposure time: 48 h Method: OECD Test Guideline 202</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l Exposure time: 72 h Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l Exposure time: 72 h Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>EC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 74 mg/l Exposure time: 72 h Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>NOEC (Pseudokirchneriella subcapitata (green algae)): 74 mg/l Exposure time: 72 h Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td>Toxicity to fish (Chronic toxicity)</td>
<td>NOEC (Pimephales promelas (fathead minnow)): 9.4 mg/l Exposure time: 32 d Method: OECD Test Guideline 210</td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</td>
<td>NOEC (Daphnia magna (Water flea)): 11 mg/l Exposure time: 21 d Method: OECD Test Guideline 211</td>
</tr>
<tr>
<td>Toxicity to microorganisms</td>
<td>EC50: &gt; 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209</td>
</tr>
</tbody>
</table>
Imipenem / Cilastatin / Relebactam Formulation

**Relebactam:**

**Toxicity to daphnia and other aquatic invertebrates**
- EC50 (Daphnia magna (Water flea)): > 100 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
- EC50 (Americamysis): > 100 mg/l
  - Exposure time: 96 h

**Toxicity to algae/aquatic plants**
- EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
- EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
- NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

**Toxicity to fish (Chronic toxicity)**
- NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**
- NOEC (Daphnia magna (Water flea)): 2.7 mg/l
  - Exposure time: 21 d
  - Method: OECD Test Guideline 211

**Toxicity to microorganisms**
- EC50: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
- NOEC: 96.3 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

**Persistence and degradability**

**Components:**

**Cilastatin:**

**Biodegradability**
- Result: Not readily biodegradable.
- Biodegradation: 27 %
- Exposure time: 28 d
- Method: OECD Test Guideline 301B
Imipenem:  
| Biodegradability | Result: Not readily biodegradable.  
| Biodegradation: 29 %  
| Exposure time: 28 d  
| Method: OECD Test Guideline 301B

Relebactam:  
| Biodegradability | Result: Not readily biodegradable.  
| Biodegradation: 11.3 %  
| Exposure time: 28 d  
| Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Cilastatin:  
| Partition coefficient: n-octanol/water | log Pow: -3.53

Imipenem:  
| Partition coefficient: n-octanol/water | log Pow: < -1

Relebactam:  
| Partition coefficient: n-octanol/water | log Pow: < -2

Mobility in soil

Components:

Cilastatin:  
| Distribution among environmental compartments | log Koc: 2.3

Relebactam:  
| Distribution among environmental compartments | log Koc: 2.3

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues: Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.
SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class : 9
Packing group : III
Labels : 9

IATA-DGR
UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Imipenem)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
UN/ID/NA number : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Imipenem)
Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171
Marine pollutant : yes (Imipenem)
Remarks : Above applies only to containers over 119 gallons or 450 liters.
Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to
facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards
- Combustible dust
- Respiratory or skin sensitization
- Reproductive toxicity
- Specific target organ toxicity (single or repeated exposure)
- Serious eye damage or eye irritation

SARA 313
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know
Cilastatin 81129-83-1
Imipenem 74431-23-5
Relebactam 1174020-13-3

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-

Version 11.0  Revision Date: 04/04/2023  SDS Number: 67748-00026  Date of last issue: 08/23/2022  Date of first issue: 02/27/2015

NFPA 704:

<table>
<thead>
<tr>
<th>Health</th>
<th>Flammability</th>
<th>Instability</th>
<th>Special hazard</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)
OSHA Z-3 : USA, Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
CAL PEL / PEL : Permissible exposure limit
OSHA Z-3 / TWA : 8-hour time weighted average

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); EOX - Concentration associated with % response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with % response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErOX - Concentration associated with % growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act;
SAFETY DATA SHEET

Imipenem / Cilastatin / Relebactam Formula-

Version 11.0  Revision Date: 04/04/2023  SDS Number: 67748-00026  Date of last issue: 08/23/2022

Revision Date: 04/04/2023

Date of first issue: 02/27/2015

REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative


Revision Date: 04/04/2023

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8